ALK and neoplasm: During EMT, tumor cells acquire enhanced migratory, invasive, and anti-apoptotic capabilities, accompanied by cytoskeletal remodeling and altered expression of hallmark molecular markers, such as downregulation of E-cadherin and upregulation of N-cadherin and vimentin, resulting in markedly reduced sensitivity to ALK inhibitors [74].